Antibody-cytokine fusion proteins are being considered as biopharmaceuticals for cancer immunotherapy. Tumor-homing cytokine fusions typically display an improved therapeutic activity compared to the corresponding unmodified cytokine products, but toxicity profiles at equivalent doses are similar, since side effects are mainly driven by the cytokine concentration in blood. In order to explore avenues to harness the therapeutic potential of antibody-cytokine fusions while decreasing potential toxicity, we compared bolus and fractionated administration modalities for two tumor-targeting antibody-cytokine fusion proteins based on human interleukin-2 (IL2) and murine tumor necrosis factor (TNF) (i.e., L19-hIL2 and L19-mTNF) in two murine immunocompetent mouse models of cancer (F9 and C51). A comparative quantitative biodistribution analysis with radio-labeled protein preparations revealed that a fractionated administration of L19-hIL2 could deliver comparable product doses to the tumor with decreased product concentration in blood and normal organs, compared to bolus injection. By contrast, L19-mTNF (a product that causes a selective vascular shutdown in the tumor) accumulated most efficiently after bolus injection.
Introduction
The successful treatment of a growing number of tumor types with immune checkpoint inhibitors [1] [2] [3] [4] [5] [6] [7] [8] [9] has stimulated the interest in the exploration of alternative and complementary approaches for the selective boosting of T cell and NK cell activity against cancer. For many years, pro-inflammatory cytokines have been considered as a promising class of biopharmaceuticals for immunotherapy applications, but the practical applicability of cytokine therapies has been limited by severe toxicity at low doses, preventing escalation to therapeutically active regimens [10, 11] . In spite of these limitations, some products have gained marketing authorization and have provided a therapeutic benefit for a small proportion of patients. Recombinant IL2 (aldesleukin, Proleukin ® ) obtained marketing authorization for the treatment of metastatic melanoma and for renal cell carcinoma [12] . Treatment with aldesleukin induced a prolonged overall survival only in a relatively small proportion of cancer patients, however substantial toxicities (e.g. vascular leak syndrome, nausea and fever) are frequently observed [13] [14] [15] . Recombinant TNF (Beromun ® ) has been approved for the treatment of soft-tissue sarcoma patients only for isolated limb perfusion procedures [16] [17] [18] [19] , whereas recombinant interferons have received marketing authorization for the treatment of various types of malignancies [20, 21] .
A number of strategies have been considered for the increase of the therapeutic index of proinflammatory cytokine payloads, including modification with cleavable polymers (de facto generating pro-drugs which regain activity upon hydrolytic loss of the polymer chains) [22] and antibody-cytokine fusions [23, 24] . We and others have previously shown that antibodycytokine fusions, capable of selective localization at the tumor site, can substantially increase therapeutic activity compared to the non-modified cytokine counterparts, when administered at equimolar doses [25] [26] [27] . L19-hIL2 and L19-hTNF are two products, which target the alternatively-spliced EDB domain of fibronectin (a marker of tumor angiogenesis) and which are currently being investigated in Phase III clinical trials for the treatment of Stage III B,C melanoma (EudraCT number: 2015-002549-72 and NCT03567889) and of metastatic softtissue sarcoma (EudraCT number: 2016-003239-38 and NCT03420014) [28] [29] [30] [31] [32] [33] .
Interleukin-2 is a monomeric protein which can easily be fused to antibodies in diabody format, a homobivalent protein architecture that exhibits superior tumor homing properties compared to monomeric scFv fragments [34] . Tumor necrosis factor features a non-covalent homotrimeric structure. ScFv fragments are normally used for the production of TNF fusions, since the use of non-covalent oligomeric structures (e.g., diabodies) would lead to TNFmediated polymerization. Fusions of TNF with scFv fragments lead to the formation of stable non-covalent homotrimers, which can display excellent tumor-targeting properties in biodistribution studies as a result of rapid extravasation and multivalent antigen recognition [25, [35] [36] [37] . The biological features of IL2-and TNF-based products, in the context of cancer immunotherapy, are considerably different. IL2 boosts the number and activity of intratumoral NK and T cells [38] , while TNF displays a more complex mechanism of action, which involves an increase in vascular permeability leading to haemorrhagic necrosis within the neoplastic mass [25, [35] [36] [37] .
While antibody-cytokine fusions can increase the therapeutic index of their payload, toxicities at equimolar doses are often comparable. This feature, which may initially appear as paradoxical, is easy to understand considering the fact that only a small amount of product (in absolute terms) reaches the tumor mass (approximately 5-20 percent injected dose per gram in mice and 0.01-0.1 percent injected dose per gram in patient) [39, 40] . Exposure of blood and normal organs to pro-inflammatory cytokines may cause hypotension, flu-like symptoms, nausea and vomiting [13] [14] [15] [16] [17] [18] [19] [20] [21] . Intense research activities are devoted to the search for methods which preserve the therapeutic activity of engineered cytokine products, while decreasing systemic toxicity [24] . Experimental strategies may include the allosteric activation of cytokine activity upon antigen binding [41] , the design of split-cytokine fusions [42] , the generation of dual-cytokine fusions [36, [43] [44] [45] [46] [47] [48] , the selective depotentiation of cytokines by mutagenesis [36, [49] [50] [51] and the use of masking antibodies to cover portions of the cytokine surface [52] .
The toxicity of cytokine therapeutics is often manifested only at concentrations above a certain critical threshold and follows a non-linear profile [22] . It has been argued that a transient inhibition of cytokine activity at early time points after intravenous administration may represent a viable strategy for the generation of better tolerated products [24] . Here, we describe an experimental approach for the administration of high doses of antibody-cytokine 6 fusion proteins, which would be lethal upon bolus injection. We reasoned that a fractionated administration in mice (or a slow infusion in patients) rather than a bolus injection should deliver comparable amounts of cytokine activity to the tumor site and keep blood concentrations below a critical threshold. We used L19-hIL2 [26] and L19-mTNF (featuring a murine cytokine moiety) [25] since these two products act by different mechanisms of action and since their full-human counterparts are being investigated in pivotal clinical trials.
Quantitative biodistribution studies with radio-iodinated protein preparations and therapy experiments in tumor-bearing mice provided insights on the usefulness of administering fractionated product doses.
Materials and Methods

Tumor cell lines and reagents
All cell lines were obtained from the ATCC with the exception of C51 colon carcinoma (kindly provided by M.P. Colombo, Istituto Nazionale Tumori, Milan, Italy). Cell lines were received between 2015 and 2017, expanded, and stored as cryopreserved aliquots in liquid nitrogen. Cells were grown according the supplier's protocol and kept in culture for no longer than 14 passages. Authentication of the cell lines also including check of postfreeze viability, growth properties, and morphology, test for mycoplasma contamination, isoenzyme assay, and sterility test were performed by the cell bank before shipment.
The clinical stage L19-hIL2 was kindly provided by Philogen S.p.A (Siena, Italy). The production and purification of the murine surrogate L19-mTNF was performed as described before [25] .
Biochemical characterization
Purified proteins were analyzed by size-exclusion chromatography on a Superdex 200 increase 10/300 GL column on an ÄKTA FPLC (GE Healthcare, Amersham Biosciences).
SDS-PAGE was performed with 10% gels (Invitrogen) under reducing and non-reducing
conditions. ESI/LC-MS was performed with an ACQUITY UPLC H class system equipped with an ACQUITY BEH300 C4 column (2.1 50 mm, 1.7-m particle size) sequentially coupled to a Waters Xevo G2-XS QTof ESI mass analyzer. Aminoacid sequences of L19-hIL2 and L19-mTNF can be found in Supplementary Figure 1 .
Immunofluorescence studies
Antigen expression was confirmed on ice-cold acetone fixed 8 µm cryostat sections of C51 and F9 tumors stained with IgG (L19)-FITC (final concentration 2 µg/mL) and detected with a Rabbit anti-FITC (Bio-Rad; 4510-7804) and Donkey anti-Rabbit AlexaFluor 488 (Invitrogen; A11008). For vascular staining Goat anti-CD31 (R&D System; AF3628) and Donkey anti-Goat AlexaFluor 594 (Invitrogen + A21209) antibodies were used. Slides were mounted with fluorescent mounting medium and analysed with fluorescent mounting medium (Dako Agilent).
Animal and tumor models
Six to eight-week-old female BALB/c mice and 129/SvEv mice were obtained from Janvier Labs. Tumor cells were implanted subcutaneously in the flank using 1.5x10 7 Organ samples were weighed and radioactivity was counted using a gamma counter. The protein uptake in the different organs was calculated and expressed as the percentage of the injected dose per gram of tissue (%ID/g ± SEM n = 5 mice/group). Data were corrected for tumor growth and no radioactivity decay adjustments were made as the half-life of 125 I is 60
days.
Therapy studies
Mice were monitored daily and tumor volume was measured with a caliper (volume = length × width 2 × 0.5). When tumors reached a suitable volume (approx. 70-100 mm 3 ), mice were injected into the lateral tail vein with the pharmacological agents.
L19-hIL2 was administered at 100 µg and 400 µg once. L19-mTNF was dissolved in PBS, also used as negative control, and administered either as a single 10 µg bolus injection or as a 5 µg fractionated dose, which was repeated three times every 24 hours for a first experiment in F9 tumor bearing mice. In a second experiment in F9 tumors the single bolus injection was reduced at a dose of 5 µg, whereas the fractionated dose (5 µg) was extended to 5 cycles every 24 hours. In the C51 tumor model L19-mTNF was administered either as a single 3 µg bolus injection or as a 1 µg or 1.5 µg fractionated dose, which was repeated three times every can, in principle, be found in the basement membrane of tumor blood vessels and/or in the tumor interstitium and stroma. These two distinct features can indeed be found in patient specimens [54] [55] [56] [57] , as well as in F9 teratocarcinomas and C51 colorectal tumors: two murine models of cancer that were used in this study. A predominantly vascular pattern of EDB expression was observed in F9 tumors, while a diffuse staining of the interstitium was seen in C51 tumors [ Figure 1B] . We used L19-hIL2 [26] and L19-mTNF [25] as representative immunostimulatory fusion proteins, in order to test the impact of dose fractionation in different models of cancer. Figure 1C [Supplementary Figure 3] , and the multimeric products showed in both cases a pure peak with the correct size (i.e., based on the elution volumes of standard proteins provided in the manufacturer's brochure) in size exclusion chromatography.
Figure 1E depicts a biodistribution rationale for using intravenous fractionated
administration of antibody-cytokine fusions, rather than intravenous bolus injection.
Biodistribution results may be displayed in terms of product concentration in tumor masses, blood or normal organs over time. Upon i.v. bolus injection adverse events (e.g., flu-like symptoms, hypotension) may occur as blood concentrations of the therapeutic agent stand above a critical threshold. Blood levels of drugs then typically decrease in a mono-or biexponential manner [58] , alongside with the progressive disappearance of side effects. [30, 31] . In parallel, the concentration of product in the solid tumor mass increases over time, in a process that slows down with the progressive disappearance of antibody-cytokine fusion from circulation. Products targeting stable antigens (e.g., components of the modified tumor extracellular matrix) exhibit long residence times within the neoplastic mass [59, 60] . It is therefore conceivable that by fractionating the administration of antibody-cytokine fusions, we may achieve a progressive build-up of product concentration within the solid tumor mass, while keeping blood levels below a critical threshold.
We tested fractionated administration strategies in quantitative biodistribution studies with radio-labeled preparations of L19-hIL2 and of L19-mTNF in immunocompetent mice, bearing murine F9 teratocarcinomas [Figure 2 ] or C51 adenocarcinomas [Supplementary Figure   2B . As expected, comparable doses in the tumor were observed for single or fractionated (2or 3-times) injection modalities. Increased tumor:organ ratios were observed when product injection was divided in three steps over a period of 72 hours [ Figure 2B ]. A different profile was observed for L19-mTNF. In that case, a progressive decrease in the cumulative %ID/g value in the tumor mass was observed [ Figure 2D ]. The targeted delivery of TNF to the tumor blood vessels may cause a rapid and selective shutdown of the vasculature, leading to hemorrhagic necrosis [25, 36, 37, 61] . The conversion of a tumor mass into a necrotic scab within the first few hours is likely to prevent product accumulation for subsequent injections.
We tested the antitumor-activity for L19-hIL2 in immunocompetent mice, bearing F9 teratocarcinomas [ Figure 3A ]. Unlike the human situation, IL2 shows minimal toxicity in mice. No body weight loss could be observed upon bolus administration of 100 µg and 400 µg L19-hIL2. The higher dose was efficacious in controlling tumor size for a long time period, but the lack of toxicity prevented a comparative evaluation of bolus vs. fractionated administration strategies. We repeated therapy experiments, comparing a single bolus injection of 400 µg L19-hIL2 with a fractionated administration of four doses of 200 µg, leading to a total cumulative dose of 800 µg. The latter regimen yielded a better control of tumor growth, even though complete regressions were not observed [ Figure 3B ].
We then tested L19-mTNF in F9 teratocarcinomas in 129/SvEv mice and in C51 colorectal Metronomic administration procedures have been extensively studied for many types of chemotherapeutic drugs, but are less characterized for cytokine-based biopharmaceuticals [62] [63] [64] . The therapeutic activity of NKTR-214 (a PEGylated derivative of IL2) in mice [22] and in patients [65] has been attributed to its ability to release free IL2 in a controlled fashion. The product is administered intravenously, the PEG chains are slowly hydrolyzed and as a consequence the drug becomes active. This strategy reduces systemic toxicities by providing minimal exposure of the free IL2, while achieving, over a period of 5 days, a 380fold increased tumor exposure of the active cytokine, compared to the unmodified IL2 (i.e., adesleukin).
Certain immunotherapeutics work better when given by continuous infusion. Blinatumomab (a bispecific antibody product in BiTE™ format) has received marketing authorization for the treatment of adult and pediatric patients with B-cell precursor acute lymphoblastic leukemia (ALL). The product is administered as 30-day continuous infusion thanks to the use of an infusion pump [66] . The same agent was found to be substantially inefficacious when administered as bolus injection [67, 68] .
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Subcutaneous injections may lead to a sustained release of immunotherapeutics.
Recombinant human IL2 has shown comparable activity (but different tolerability) when given as subcutaneous administration or as bolus injection [69] . An engineered version of human interleukin-15 ALT-803) has recently shown superior biodistribution and activity profiles when administered as subcutaneous injections, while a rapid disappearance from circulation and elevated toxicity was reported for bolus intravenous administration [70] .
From a theoretical viewpoint, we would expect dose fractionation to be associated with a better tolerability profile and, indeed, this feature was observed for L19-mTNF in murine models of cancer. However, the different therapeutic performance of this product in F9 and 
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